Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

Autologous Bone Marrow Infusion Study for Sensorineural Hearing Loss

Also known as: Autologous Bone Marrow Infusion, Bone marrow mononuclear fraction infusion, BMMF infusion

Investigator-led study

Primary source

Sponsor / Institution

Investigator-led study

Program Type

Therapeutic

Modality

Cell Therapy

Stage

Phase 1/2

Status

Paused

Target Gene

—

Route / Mode

Intravenous infusion

Confidence

72%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

United States

Population

pediatric, sensorineural, study-level

Trial IDs

Mechanism

Single-arm investigator-led study of intravenous autologous bone marrow mononuclear cells harvested from the patient and infused for pediatric sensorineural hearing loss.

Indications

Hearing Loss Sensorineural Hearing Loss

Notes

ClinicalTrials.gov verifies a suspended investigator-led Phase 1/2 safety and feasibility study of autologous bone marrow mononuclear fraction infusion in children with bilateral moderate-to-severe sensorineural hearing loss. This is not a confirmed commercial pipeline asset and should be interpreted as a registry-verified study-level record.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT02616172

Open

Key Events

2015-10-01

Registry-listed study start for autologous bone marrow infusion in pediatric sensorineural hearing loss

2022-09-01

Registry estimated completion date passed while study remained suspended

Clinical Trials (1)